- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00320580
An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen
June 30, 2011 updated by: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
A Randomized, Open-Label, Multicenter Study Comparing the Bleeding Profile of Ortho Evra (Norelgestromin/Ethinyl Estradiol) Continuous Regimen vs. Ortho Evra Cyclic Regimen
The purpose of this study is to compare the bleeding profile of norelgestromin/ethinyl estradiol given in an extended continuous regimen to norelgestromin/ethinyl estradiol given in a traditional cyclic regimen
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Norelgestromin/ethinyl estradiol is a contraceptive patch shown to be safe and effective for the prevention of pregnancy.
The usual treatment regimen is three consecutive seven-day patches followed by one patch-free week.
This cyclic method is followed in order to mimic the 28-day menstrual cycle.
An extended contraceptive regimen (administration of active hormones for greater than 21 days) of oral contraceptives is a common practice among women wishing to delay or prevent withdrawal bleeding for reasons such as athletic participation or going on vacation.
In addition to the convenience of reducing the frequency of withdrawal bleeds, elimination of the hormone-free interval reportedly reduces many menstrually-related symptoms (headaches, pelvic pain, breast tenderness, bloating, swelling) that occur at a greater frequency during the hormone-free interval than during the rest of the cycle.
Headache is one of the most common adverse effects associated with hormonal contraceptive use.
Studies have demonstrated that headaches were reduced in subjects using extended intervals of active hormone.
However, one of the main side effects reported with extended regimens is breakthrough bleeding and/or spotting.
Compared to cyclic regimens, extended oral contraceptive use may be associated with an increased incidence of breakthrough bleeding and spotting, especially during the first few months of use.
This is a randomized (patients are assigned different treatments based on chance), open-label, multicenter study comparing the bleeding profile of norelgestromin/ethinyl estradiol patch continuous regimen to norelgestromin/ethinyl estradiol patch cyclic regimen.
Safety evaluations include adverse event reporting, physical examinations, blood levels, and vital signs.
The hypothesis of the study is that norelgestromin/ethinyl estradiol in an extended regimen of 84 days of active hormone would result in fewer days and episodes of bleeding compared to a traditional cyclic regimen of norelgestromin/ethinyl estradiol.
Patients receive norelgestromin/ethinyl estradiol patches in a plastic sleeve.
In the extended regimen patches will be applied weekly for 12 consecutive weeks followed by one week patch-free and then another three consecutive weeks of weekly patch applications.
In the cyclic regimen patches will be applied for four consecutive cycles where each cycle consists of three weekly patch applications followed by one week patch-free.
The total duration of treatment period is 112 days for each regimen.
Study Type
Interventional
Enrollment (Actual)
239
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients in good health as confirmed by medical history
- not pregnant as demonstrated by negative urine pregnancy test
- completed their last term pregnancy at least 42 days prior to Screening and at least one normal menstrual period since last pregnancy
- not lactating
- post-menarcheal and pre-menopausal
Exclusion Criteria:
- History or presence of disorders commonly accepted as contraindications to steroid hormonal therapy including but not limited to the following - active or history of deep vein thrombophlebitis or thromboembolytic disorders or hypercoagulation disorders, cerebral vascular or coronary artery disease, uncontrolled hypertension, or migraines with focal aura, benign or malignant liver tumor which developed during the use of oral contraceptives or estrogen-containing products
- treatment with continuous oral contraception within three months of study
- previous use of contraceptive patch including norelgestromin/ethinyl estradiol
- patients who are amenorrheic (abnormal suppression or absence of menstruation)
- recent history of alcohol or substance abuse
- skin conditions resulting in oily, irritated or damaged skin at potential sites of application
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 001
norelgestromin/ethinyl estradiol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary efficacy variables are the total number bleeding and/or spotting days during the 84-day reference period and the number of bleeding and/or spotting episodes during the 84-day reference period.
|
Secondary Outcome Measures
Outcome Measure |
---|
Secondary efficacy variables include the number of breakthrough bleeding and/or spotting days per 28-day interval, the number of breakthrough bleeding days per 28-day interval, time to first bleeding and/or spotting, duration of menses.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Stewart FH, Kaunitz AM, Laguardia KD, Karvois DL, Fisher AC, Friedman AJ. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol. 2005 Jun;105(6):1389-96. doi: 10.1097/01.AOG.0000160430.61799.f6.
- LaGuardia KD, Fisher AC, Bainbridge JD, LoCoco JM, Friedman AJ. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril. 2005 Jun;83(6):1875-7. doi: 10.1016/j.fertnstert.2004.12.048.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Completion (Actual)
March 1, 2003
Study Registration Dates
First Submitted
April 28, 2006
First Submitted That Met QC Criteria
April 28, 2006
First Posted (Estimate)
May 3, 2006
Study Record Updates
Last Update Posted (Estimate)
July 1, 2011
Last Update Submitted That Met QC Criteria
June 30, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Uterine Diseases
- Uterine Hemorrhage
- Hemorrhage
- Metrorrhagia
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Hormonal
- Estradiol
- Ethinyl Estradiol
- Norelgestromin
Other Study ID Numbers
- CR008335
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metrorrhagia
-
Ain Shams UniversityCompletedPremenopausal; MetrorrhagiaEgypt
-
Columbia UniversityCompletedMetrorrhagiaUnited States
-
University of HawaiiMeharry Medical College; Charles Drew University of Medicine and ScienceCompletedBreakthrough BleedingUnited States
-
Brugmann University HospitalCompletedMetrorrhagiaBelgium
-
Eurofarma Laboratorios S.A.Withdrawn
-
Duramed ResearchCompletedBreakthrough BleedingUnited States
-
Oregon Health and Science UniversityCompletedBreakthrough BleedingUnited States
-
McNeil Consumer & Specialty Pharmaceuticals, a...Completed
-
Oregon Health and Science UniversityMerck Sharp & Dohme LLCActive, not recruitingBleeding | Breakthrough Bleeding | ImplantsUnited States
-
University of Sao PauloMerck Sharp & Dohme LLCRecruitingBreakthrough BleedingBrazil
Clinical Trials on norelgestromin/ethinyl estradiol
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Janssen-Ortho Inc., CanadaCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
University of VermontUniversity of Vermont Medical CenterCompletedVenous Thrombosis
-
University of OuluCompleted
-
University of PittsburghOrganonCompletedContraceptionUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed